<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03284255</url>
  </required_header>
  <id_info>
    <org_study_id>BXA2017001</org_study_id>
    <nct_id>NCT03284255</nct_id>
  </id_info>
  <brief_title>Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study</brief_title>
  <official_title>A Randomized Controlled Trial of the Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System in Patients With Coronary Artery Disease: BIOHEART-II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Bio-heart Biological Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CCRF Inc., Beijing, China</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Bio-heart Biological Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Bioheart Randomized Controlled Trial is a prospective multicentred paralleled study,&#xD;
      which will enroll 430 patients and randomized 1:1 to study group and control group. Aim to&#xD;
      assess the efficacy and safety of Rapamycin Drug-Eluting Bioresorbable Coronary Stent System&#xD;
      compare with XIENCE stent in the treatment of patients with up to two coronary lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, multicentred randomized controlled trial, planning to enroll 430&#xD;
      subjects and randomize 1:1 to study group and control group.&#xD;
&#xD;
      All subjects will accept clinical evaluation at 1 month, 6 month, 9 month and 1, 2, 3, 4, 5&#xD;
      year post procedure.&#xD;
&#xD;
      All subjects will accept angiographic evaluation at 1 year post procedure, and simutaneously&#xD;
      80 subjects (40 in study group and 40 in control group) will accepted OCT evaluation.&#xD;
&#xD;
      To assess the efficacy and safety, the primary endpoint will be in segment late luminal loss&#xD;
      at 1 year post procedure, the secondary endpoint is neointima coverage percentage of stent&#xD;
      strut (%) at 1 year post procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 11, 2017</start_date>
  <completion_date type="Anticipated">August 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>in segment late luminal loss</measure>
    <time_frame>1 year post procedure</time_frame>
    <description>In-segment late loss is defined as the change in minimal lumen diameter (MLD) from post-procedure to 1 year by angiography，in segment is defined within the margins of the scaffold/stent and 5 mm proximal and 5 mm distal to the scaffold/stent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>neointima coverage percentage of stent strut (%)</measure>
    <time_frame>1 year post procedure</time_frame>
    <description>only in OCT subgroup</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>device success</measure>
    <time_frame>immediately post procedure</time_frame>
    <description>defined as attainment of residual stenosis less than 30% by visual estimation and TIMI flow grade 3 post stent implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lesion success</measure>
    <time_frame>immediately post procedure</time_frame>
    <description>defined as attainment of diameter residual stenosis less than 30% by visual estimation and TIMI flow grade 3, after the target lesion treated by any PCI methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical success</measure>
    <time_frame>at 1 month post procedure</time_frame>
    <description>defined as attainment of lesion success and without any major adverse cardiac events during hospitalization (up to 7 days after proceduce)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device oriented composite endpoint (DoCE)/target lesion failure (TLF)</measure>
    <time_frame>at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure</time_frame>
    <description>defined as Cardiac Death, target vessel - myocardial infarction (TV-MI), and ischemic driven - target lesion revascularization (ID-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient oriented composite endpoint (PoCE)</measure>
    <time_frame>at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure</time_frame>
    <description>defined as all caused death, any myocardial infarction, and any revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure</time_frame>
    <description>cardiac death, vascular death, non-cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction (MI)</measure>
    <time_frame>at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure</time_frame>
    <description>target vessel MI, non-target vessel MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target lesion revascularization</measure>
    <time_frame>at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure</time_frame>
    <description>ischemic driven, non-ischemic driven</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target vessel revascularization</measure>
    <time_frame>at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure</time_frame>
    <description>ischemic driven, non-ischemic driven</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any coronary revascularization</measure>
    <time_frame>at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARC--defined stent thrombosis</measure>
    <time_frame>at 1, 6, 9 month and1, 2, 3, 4, 5 year post procedure</time_frame>
    <description>timing (acute, subacute, late and very late stent thrombosis); relationship (definite, probable and possible stent thrombosis)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>angiographic endpoints-acute stent recoil</measure>
    <time_frame>immediately post procedure</time_frame>
    <description>assess in milimeter</description>
  </other_outcome>
  <other_outcome>
    <measure>angiographic endpoints-late lumen loss (LLL)</measure>
    <time_frame>immediately and 1 year post procedure</time_frame>
    <description>include in stent, 5mm proximal and distal to the stent；</description>
  </other_outcome>
  <other_outcome>
    <measure>angiographic endpoints-minimal lumen diameter (MLD)</measure>
    <time_frame>immediately and 1 year post procedure</time_frame>
    <description>include in stent, 5mm proximal and distal to the stent and in segment；</description>
  </other_outcome>
  <other_outcome>
    <measure>angiographic endpoints-diameter stenosis (DS),</measure>
    <time_frame>immediately and 1 year post procedure</time_frame>
    <description>assess in percentage, include in stent, 5mm proximal and distal to the stent and in segment；</description>
  </other_outcome>
  <other_outcome>
    <measure>angiographic endpoints-angiographic binary restenosis (ABR),</measure>
    <time_frame>1 year post procedure</time_frame>
    <description>assess in percentage, include in stent, 5mm proximal and distal to the stent and in segment.</description>
  </other_outcome>
  <other_outcome>
    <measure>OCT imaging endpoints-Neointimal tissue thickness</measure>
    <time_frame>1 year post procedure</time_frame>
    <description>assess in millimeter</description>
  </other_outcome>
  <other_outcome>
    <measure>OCT imaging endpoints-late acquired stent malapposition</measure>
    <time_frame>1 year post procedure</time_frame>
    <description>assess in millimeter</description>
  </other_outcome>
  <other_outcome>
    <measure>OCT imaging endpoints-Volume obstruction percentage</measure>
    <time_frame>1 year post procedure</time_frame>
    <description>assess in percentage</description>
  </other_outcome>
  <other_outcome>
    <measure>OCT imaging endpoints-Late stent recoil</measure>
    <time_frame>1 year post procedure</time_frame>
    <description>assess both in percentage and square millimeter</description>
  </other_outcome>
  <other_outcome>
    <measure>OCT imaging endpoints-Neointimal Healing Score</measure>
    <time_frame>1 year post procedure</time_frame>
    <description>will be calculated by OCT imaging software</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">431</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Antineoplastic Agents</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in this group the subject will accept the treatment of BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>in this group the subject will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>study group</intervention_name>
    <description>study group in which patient will accept the treatment of Bioresorbable Coronary Stent</description>
    <arm_group_label>study group</arm_group_label>
    <other_name>BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>control group</intervention_name>
    <description>control group in which patient will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        subjects that participate in this study must fulfill all the following criteria:&#xD;
&#xD;
        general inclusion criteria:&#xD;
&#xD;
          1. Age from 18 to 75 years old, man or non-pregnant woman;&#xD;
&#xD;
          2. Subjects with asymptomatic ischemic evidence, stable or unstable angina, or old&#xD;
             myocardial infarction, suitable for selective PCI;&#xD;
&#xD;
          3. Subjects without contraindications of coronary artery bypass grafting (CABG);&#xD;
&#xD;
          4. Subjects are able to understand the purpose of this study, volunteer to participate&#xD;
             and sign informed consent, willing to accept invasive imaging follow-up.&#xD;
&#xD;
        Angiographic inclusion criteria:&#xD;
&#xD;
          1. One or two de novo target lesions&#xD;
&#xD;
               1. If subject has only one target lesion, the second non-target lesion can be&#xD;
                  treated but this non-target lesion must locate in a different epicardial vessel,&#xD;
                  and must be treated first and be treated successfully prior to the subjects'&#xD;
                  randomization.&#xD;
&#xD;
               2. If there are two target lesions, they must locate in different epicardial vessels&#xD;
                  and both satisfy the angiographic eligibility criteria.&#xD;
&#xD;
               3. The definition of epicardial vessels means the left anterior descending artery&#xD;
                  (LAD), the left circumflex artery (LCX), and the right coronary artery (RCA) and&#xD;
                  their branches. Thus, for example, the subject must not have lesions requiring&#xD;
                  treatment in both the LAD and a diagonal branch&#xD;
&#xD;
          2. Target lesion diameter stenosis ≥ 70% (or ≥ 50% simultaneously shall have clinical&#xD;
             evidence of myocardial ischemia), and TIMI flow grade ≥1; Target lesion length ≤24mm&#xD;
             (visually); target lesion diameter between ≥ 2.5 mm to ≤ 4.00 mm.&#xD;
&#xD;
          3. Each target lesion can be fully covered by one stent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        If subjects fulfill any of below criterias, this subject shall be exclude from this study.&#xD;
&#xD;
        general exclusion criteria:&#xD;
&#xD;
          1. Any newly onset acute myocardial infarction within 1 week or, myocardial enzymes does&#xD;
             not return to normal level after myocardial infarction;&#xD;
&#xD;
          2. Target lesion has any stents implant history within 1 year or subjects planning to&#xD;
             receive percutaneous artery intervention within half one year;&#xD;
&#xD;
          3. Subjects with severe heart failure (≥ grade III NYHA) or left ventricular ejection&#xD;
             fraction &lt;35% (accessed by ultrasound or left ventricular angiography)&#xD;
&#xD;
          4. Preprocedure severe kidney functional damaged: serum creatinine&gt; 2.0mg /dl (176.8μmol&#xD;
             / L) or subject is receiving hemodialysis;&#xD;
&#xD;
          5. Subjects with bleeding tendency, active gastrointestinal ulcers, history of cerebral&#xD;
             hemorrhage or history of subarachnoid hemorrhage, history within six months of&#xD;
             ischemic stroke, contraindications of anti-platelet agents and anticoagulants&#xD;
             treatment, and subjects cannot receive anti-thrombolytic therapy;&#xD;
&#xD;
          6. Hypersensitive or allergic to aspirin, clopidogrel, heparin, contrast agent,&#xD;
             polylactic acid polymer， rapamycin;&#xD;
&#xD;
          7. The subject's life expectancy is less than 24 months;&#xD;
&#xD;
          8. Subjects participated in other drug or medical device clinical trial and have not&#xD;
             reach the primary endpoint;&#xD;
&#xD;
          9. Investigators determine the subjects' compliance is poor, cannot complete the study as&#xD;
             required;&#xD;
&#xD;
         10. Subjects have accepted substantial organ transplant or ready to undergo organ&#xD;
             transplant;&#xD;
&#xD;
         11. Subjects have unstable arrhythmia, such as high-risk ventricular premature beats, and&#xD;
             ventricular tachycardia;&#xD;
&#xD;
         12. Subjects need to receive chemotherapy because of tumor;&#xD;
&#xD;
         13. Subjects have received or planning to receive coronary or chest radiotherapy;&#xD;
&#xD;
         14. Subjects with Immunosuppressive, autoimmune diseases, are planned or undergoing&#xD;
             immunosuppressive therapy;&#xD;
&#xD;
         15. Subjects are planning to receive or are receiving long-term anticoagulation therapy,&#xD;
             such as heparin, warfarin and so on;&#xD;
&#xD;
         16. Subjects are planning to accept selective surgery within 6 months, need to discontinue&#xD;
             aspirin or clopidogrel;&#xD;
&#xD;
         17. Blood tests showed that the platelet count is less than 100 × 109 / L, or over than&#xD;
             700 × 109 / L, the white blood cells count is less than 3 × 109 / L;&#xD;
&#xD;
         18. Diagnosed or suspected liver disease (such as hepatic cirrhosis);&#xD;
&#xD;
         19. Subjects with diffuse peripheral vascular disease, cannot use 6F catheter.&#xD;
&#xD;
        angiographic exclusion criteria&#xD;
&#xD;
        these exclusion criteria apply to the target or non-target lesion(s), target or non-target&#xD;
        vessel(s)&#xD;
&#xD;
          1. Target or non-target lesion(s) located in left main;&#xD;
&#xD;
          2. Subjects with coronary artery triple vessel lesion in LAD, LCX or RCA, all need to be&#xD;
             treated.&#xD;
&#xD;
        these exclusion criteria apply to the target lesion(s) or target vessel(s)&#xD;
&#xD;
          1. Target lesion located in left main;&#xD;
&#xD;
          2. Target lesion located in the aorto-ostial of RCA (within 3 mm of the origin of the&#xD;
             RCA);&#xD;
&#xD;
          3. Target lesion located within 3 mm of the origin of the LAD and LCX;&#xD;
&#xD;
          4. Lesion involving a bifurcation with a:&#xD;
&#xD;
               1. Side branch ≥ 2.5 mm in diameter, or&#xD;
&#xD;
               2. Side branch with diameter stenosis ≥ 50%, or&#xD;
&#xD;
               3. Side branch requiring protection guide wire, or&#xD;
&#xD;
               4. Side branch requiring pre-dilatation.&#xD;
&#xD;
          5. Anatomy proximal to or within the lesion that may affect delivery of the Bioheart or&#xD;
             XIENCE stent, including:&#xD;
&#xD;
               1. Extreme angulation (≥ 90°) proximal to or within the target lesion, or&#xD;
&#xD;
               2. Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion,&#xD;
                  or&#xD;
&#xD;
               3. Moderate or heavy calcification proximal to or within the target lesion&#xD;
&#xD;
          6. Target lesion involves a myocardial bridge.&#xD;
&#xD;
          7. Target vessel contains thrombus as indicated in the angiographic images or IVUS.&#xD;
&#xD;
          8. Prior to the index procedure target vessel has been previously treated with a stent at&#xD;
             any time such that the Bioheart or XIENCE stent would need to cross the stent to reach&#xD;
             the target lesion.&#xD;
&#xD;
          9. Target vessel has been previously treated with a stent and the target lesion is within&#xD;
             5 mm proximal to a previously treated lesion.&#xD;
&#xD;
         10. Target lesion cannot reach the following outcomes, after the complete balloon&#xD;
             pre-dilatation:&#xD;
&#xD;
               1. Residual (DS %) is &lt; 40% (per visual estimation), ≤ 20% is strongly recommended;&#xD;
&#xD;
               2. TIMI Grade-3 flow (per visual estimation);&#xD;
&#xD;
               3. No angiographic complications (e.g., no-reflow, distal embolization, side branch&#xD;
                  closure)&#xD;
&#xD;
               4. No dissections NHLBI grade D-F;&#xD;
&#xD;
               5. No chest pain lasting &gt; 5 minutes, and;&#xD;
&#xD;
               6. No ST depression or elevation lasting &gt; 5 minutes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shubin Qiao, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital Chinese Academy of Medical Sciences (CAMS)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bo Xu, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Fuwai Hospital Chinese Academy of Medical Sciences (CAMS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BeijingChao-YangHospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fuwai Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Frist Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhujiang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan People's Hospital</name>
      <address>
        <city>Zhongshan</city>
        <state>Gunagdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cangzhou Central Hospital</name>
      <address>
        <city>Cangzhou</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tangshan Gongren Hospital</name>
      <address>
        <city>Tangshan</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liaocheng People's Hospital</name>
      <address>
        <city>Liaocheng</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Dongfang Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital-Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inner Mongolia Autonomous Region People's Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>The Inner Mongolia Autonomous Region</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taida International Cardioascular Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 27, 2017</study_first_submitted>
  <study_first_submitted_qc>September 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 15, 2017</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioresorbable Vascular Scaffold System</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Cardiac Catheterization</keyword>
  <keyword>Tomography, Optical Coherence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

